Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
16 participants
INTERVENTIONAL
2017-03-06
2018-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Older adults, aged 61-80 years
Hepatitis B vaccine
1.0 ml (20 micrograms) suspension of hepatitis B surface antigen for intramuscular injection
Group 2
Younger adults, aged 40-60 years
Hepatitis B vaccine
1.0 ml (20 micrograms) suspension of hepatitis B surface antigen for intramuscular injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hepatitis B vaccine
1.0 ml (20 micrograms) suspension of hepatitis B surface antigen for intramuscular injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No history of hepatitis B disease.
* No prior receipt of any hepatitis B-containing vaccine.
* Undetectable level of anti-HBs and anti-HBc antibody and HBs antigen at study enrolment (indicating no evidence of prior hepatitis B vaccination or infection).
* Generally good health (stable chronic conditions acceptable), living independently or with minimal assistance (Clinical Frailty score 1-5) and able to attend clinic appointments.
* Willing and able to comply with the requirements of the protocol.
* Has given informed consent for participation in the study.
Exclusion Criteria
* Individual who is on the delegation log for this study
* History of being a household contact of a known hepatitis B-infected individual.
* Planned administration of any vaccine not specified in the study protocol from 1 month pre- to the 1 month post-1st dose of vaccine.
* Planned receipt of any investigational drug for the duration of the study.
* Confirmed or suspected immunodeficiency.
* A family history of congenital or hereditary immunodeficiency.
* Receipt of more than 1 week of immunosuppressants or immune modifying drugs (e.g. oral prednisolone \>0.5ml/kg/day or intravenous glucocorticoid steroid) in the 3 months prior to dose 1 of vaccine. Nasal, topical or inhaled steroids are allowed.
* Currently taking any anti-platelet or anti-coagulant medications (does not include daily low-dose aspirin).
* Bleeding disorder or thrombocytopenia, that contraindicates IM injection, blood collection and/or lymph node fine needle aspiration.
* Administration of immunoglobulins within the prior 12 months and/or any other blood products within the prior 3 months or planned during the study period.
* Current pregnancy or planning to become pregnant in the 6 months post-dose 1 vaccination.
* History of allergy to any component of the vaccine.
* Unstable medical condition, as indicated by a requirement for hospitalization or a substantial medication change to stabilize said condition within previous 3 months.
* History of any neurologic disorders or seizures, including a history of Guillain-Barre syndrome.
* Clinical Frailty score of 6-7 (moderately frail or severely frail).
* Scheduled elective surgery or other procedures requiring general anaesthesia from 1 month pre- to the 1 month post-1st dose of vaccine.
* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
* Temporary exclusion if acute symptomatic illness in the 7 days prior to planned first vaccine dose - vaccination will be delayed, but participant can remain in the study.
40 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vanderbilt University
OTHER
J. Craig Venter Institute
OTHER
The Scripps Research Institute
OTHER
University of California, San Diego
OTHER
Institut Pasteur
INDUSTRY
Human Vaccines Project
OTHER
University of British Columbia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Manish Sadarangani
Principle Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Manish Sadarangani
Role: PRINCIPAL_INVESTIGATOR
University of British Columbia
Tobi Kollmann
Role: PRINCIPAL_INVESTIGATOR
University of British Columbia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vaccine Evaluation Center
Vancouver, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H17-00175
Identifier Type: -
Identifier Source: org_study_id